Left atrial appendage morphology, echocardiographic characterization, procedural data and in-hospital outcome of patients receiving left atrial appendage occlusion device implantation: a prospective observational study by unknown
RESEARCH ARTICLE Open Access
Left atrial appendage morphology,
echocardiographic characterization,
procedural data and in-hospital outcome of
patients receiving left atrial appendage
occlusion device implantation: a
prospective observational study
Christian Fastner1*, Michael Behnes1, Benjamin Sartorius1, Mustafa Yildiz2, Kambis Mashayekhi3,
Ibrahim El-Battrawy1, Ralf Lehmann1, Stefan Baumann1, Tobias Becher1, Martin Borggrefe1 and Ibrahim Akin1
Abstract
Background: Implantation of left atrial appendage (LAA) occlusion devices was shown to be a feasible and effective
alternative to oral anticoagulation in patients with non-valvular atrial fibrillation. However, only few data about
in-hospital and peri-procedural data are currently available. This study aims to report about echocardiographic,
procedural and in-hospital data of patients receiving LAA occlusion devices.
Methods: This single-center, prospective and observational study includes consecutively patients being eligible
for percutaneous implantation of LAA occlusion devices (either Watchman™ or Amplatzer™ Cardiac Plug 2). Data on
pre- and peri-procedural transesophageal echocardiography (TEE), implantation and procedure related in-hospital
complications were collected. The primary efficacy outcome measure was a successful device implantation without
relevant peri-device leaks (i.e., < 5 mm).
Results: In total, 37 patients were included, 22 receiving the Watchman™ and 15 ACP 2 device. Baseline characteristics
did not differ significantly in both patient groups. The primary efficacy outcome measure was reached in 91.9 % of
patients (90.9 % for the Watchman™, 93.3 % for the ACP 2 group). One device embolization (Watchman™ group) with
successful retrieval occurred (2.7 % of patients). No thromboembolism or device thrombosis were present. The majority
of bleedings was caused by access site bleedings (88.3 % of all bleedings), consisting mostly of mild hematomas
corresponding to a BARC type 1 bleeding (80.0 % of all access-site complications). One patient died due to septic shock
(non-procedure related).
Conclusions: In daily real-life practice, percutaneous treatment with LAA occlusion devices appears to be an effective
and safe.
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Background
Atrial fibrillation (AF) represents the most common car-
diac arrhythmia with a current age-dependent preva-
lence of 1–2 % in the Western population, while being
assumed to rise significantly within the next couple of
years [1]. Cerebral ischemic stroke represents the most
important fatal complication of AF deteriorating the
prognosis of each individual patient. In the presence of
AF, the risk of stroke increases about 5-times [2], being
accompanied by a stroke-related mortality rate of about
20 % [3, 4] and a high percentage of patients remaining
disabled. The so called CHA2DS2-VASc score assesses
the patient’s individual annual stroke risk and allows a
specific risk-adapted anticoagulant treatment [5].
Oral anticoagulation (OAC) with vitamin K antago-
nists or with new direct oral anticoagulants (DOACs)
prevents effectively thromboembolic events in patients
with at least one risk factor [6]. In contrast, major
bleedings-particularly cerebral bleedings-still represent a
most crucial complication of OAC, despite the fact that
DOACs were shown to reduce the occurrence of intra-
cranial hemorrhage [7]. The individual bleeding risk as
assessed by the HAS-BLED score [5], contraindications
against OAC and the patient’s preference to deny OAC,
need to be considered before initiating OAC. In daily
clinical practice, half of patients with an increased risk
for thromboembolic complications and without any contra-
indication against OAC does not receive this treatment [8].
The percutaneous implantation of left atrial appendage
(LAA) occlusion devices such as the Watchman™ device
(Boston Scientific, Natick, MA) and the Amplatzer™ Car-
diac Plug (ACP) replaced by the Amplatzer™ Amulet™
(also known as ACP 2, both St. Jude Medical, St. Paul,
MN) was evaluated as an effective alternative to OAC in
patients with non-valvular AF and concomitant high
bleeding risk or in patients being unwilling to take life-
long OAC. The non-inferiority to warfarin therapy in
patients being eligible for OAC was proven in the
PROTECT-AF trial for the Watchman™ device [9]. Here,
warfarin was prescribed for at least 45 days after suc-
cessful device implantation. In subsequent studies dual
antiplatelet therapy (DAPT) for at least 6 months after
implantation was shown to be safe in patients with
contraindications for OAC [10]. With regard to the ACP
device, a non-inferiority study has not yet been investi-
gated. However, DAPT was shown to be safe and effective
for this device [11]. First clinical experience with the ACP
2 did not show significant differences compared to the
original ACP with regard to peri- and post-procedural
complications [12].
Although the implantation of LAA occlusion devices
is well established, there is still a great lack of in-hospital
and peri-procedural data addressing the safety and efficacy
of these devices [12–19]. Specifically, peri-procedural data
have been shown to vary tremendously between individual
centers. Today, an increase of and peri-procedural safety
has developed compared to early implantation periods
[13, 14, 20]. Therefore, this study aims to comparatively
evaluate in-hospital single-center registry data of pa-
tients scheduled for LAA occlusion device implantation
(i.e., Watchman™ versus ACP 2).
Methods
Enrollment
The present study is a single-center, prospective, obser-
vational, descriptional and non-randomized registry in-
cluding consecutively 37 patients with all three types of
non-valvular AF, a CHA2DS2-VASc score ≥ 2 and, there-
fore, indication for OAC. Patient enrollment started in
June 2014. Further inclusion criteria were age ≥ 18 years,
any relative or absolute contraindication for standard
OAC - i.e., major bleeding with tendency to recidivity,
HAS-BLED score ≥ 3 and neurological symptoms during
treatment with OAC or intolerance to OAC. Written in-
formed consent was obtained from all study patients. Pa-
tients were excluded if at least one of the following
criteria were evident: single episode of AF or treatable
reason for AF, catheter ablation of AF within 30 days
prior to or after potential LAA occluder implantation,
electrical cardioversion within 30 days after potential
occluder implantation, congestive heart failure corre-
sponding to functional class NYHA IV, myocardial in-
farction within the last 3 months, atrial septum defect or
interventional/surgical occlusion of ASD, mechanical
heart valve, status after heart transplant, symptomatic
carotid artery stenosis, transient ischemic attack (TIA) or
stroke within last 30 days, intracerebral bleeding within
the last 3 months, acute infection, existing or planned
pregnancy, existing thrombus. The study was carried out
according to the principles of the declaration of Helsinki
and was approved by the medical ethics committee II
of the Faculty of Medicine Mannheim, University of
Heidelberg, Germany.
Procedure
An electrocardiogram (ECG), standard blood analyses
and transesophageal echocardiography (TEE) were per-
formed for pre-procedural planning. LAA occlusion
device implantation was performed by experienced inter-
ventional cardiologists (≥50 LAA closure device implan-
tations each prior to the study). Patients were treated
with conscious sedation using intravenous 2,6-di(pro-
pan-2-yl)phenol and midazolam. One arterial access
sheath (5 French, F) for arterial blood pressure moni-
toring and one venous access sheath for interventional
device implantation were used. Transseptal puncture was
performed with a SL1 sheath and BRK1 Brockenbrough
needle (St. Jude Medical, St. Paul, MN). Prior transseptal
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puncture heparin was administered to achieve an active
clotting time of at least 250 s. A stiff guide wire (Cook
Medical, Bloomington, IN) was placed in the left upper
pulmonary vein (LUPV) and the transseptal sheath was
removed and replaced by the Watchman™ (14 F), re-
spectively ACP 2 (12 or 14 F) delivery sheath. Device
allocation algorithm was performed according to latest
consensus recommendations [21]. All patients under-
went pre-procedural 2D/3D TEE to assess initially the
anatomy, size and absence of thrombus or sludge on all
recommended TEE views. Accordingly, peri-procedural
imaging was based on fluoroscopy and 2D/3D TEE im-
aging in order to re-assess prior findings of the LAA
and to decide which device size was appropriate in the
individual patient. Fluoroscopy was performed using a
5 F pigtail catheter to visualize the LAA in at least 2
standard angulations (RAO 30°/10° cranial, RAO 30°/
10° caudal). Regarding TEE, the following parameters of
the LAA were assessed for appropriate sizing, as rec-
ommended for both devices [21]: LAA ostium, landing
zone, angle of the LAA, depth of the LAA, differenti-
ation of main lobes versus smaller side lobes. The
device size was chosen at least 20 % larger than the
measured diameters at the landing zone [22]. Post-
implantation the compression of the devices was mea-
sured by 2D TEE and a device compression of at least
10 % was defined as valuable, next to lacking of relevant
peri-device leaks (>5 mm), and no compression or at-
tachment of neighboring structures, such as the cir-
cumflex coronary artery, mitral annulus or pulmonary
veins. A tug test was performed repetitively before final
liberation of the device as recommended. Access site
was closed with an Angio-Seal™ Evolution™ (St. Jude
Medical, St. Paul, MN) for the arterial access and with
two ProGlide™ (Abbott Vascular, Santa Clara, CA) for
the venous access and followed by a pressure band for
6 hours.
Post-procedural measures
In accordance with our institutional protocol, acetylsali-
cylic acid (ASA) 100 mg/d was administered lifelong,
clopidogrel for at least 6 months commencing the day of
implantation with a loading dose of 250 mg, respectively
600 mg, if not taken before. The day after the procedure,
a transthoracic echocardiogram (TTE) and a chest X-ray
were performed to rule out device dislodgement and
pericardial effusion, an ECG was performed to rule out a
new bundle branch block (BBB) or atrioventricular (AV)
block and repetitive thorough clinical examinations were
carried out to rule out other clinical disorders.
Outcome measures
The primary efficacy outcome measure of our in-hospital
register was defined as technical success with a successful
device implantation without relevant peri-device leaks
(i.e., < 5 mm). Primary safety outcome measure was de-
fined as the occurrence of bleeding events classified ac-
cording to the BARC definition [23], pericardial effusion,
device embolization, peri-procedural stroke and peri-
procedural death. Events resulting in death, aggravated
morbidity or prolonged hospitalization being associated
with the procedure were defined as complications. Any
events not being associated with the procedure were
termed adverse events.
Statistics
Statistical analyses were performed with SPSS Statistics
(IBM, Armonk, NY). Descriptive statistics are given as
medians (25th and 75th percentiles) or as total numbers
with group-related percentages. Normal distribution of
data was tested with the Kolmogorov-Smirnov test. In
case of normal distribution, the t-test was applied to
compare scaled data. Scaled variables not normally dis-
tributed were compared using the Mann-Whitney U
test. Categorical variables were compared using the chi-




Baseline demographic and clinical characteristics of the
study population including indications for implantation
of LAA occlusion devices and risk-stratification according
to CHA2DS2-VASc and HAS-BLED scores are shown in
Table 1. Of 37 patients, 22 patients received the Watch-
man™ and 15 patients received the ACP 2 device. The
most common indication was a prior history of bleedings
(78.4 %) under treatment with OAC. 51.4 % of all patients
were not treated with OAC, whereas patients with OAC
were mostly treated with DOAC (66.7 %). Table 2 shows
two-dimensional (2D) and functional echocardiographic
measurements. As assessed by angiography, the majority
of patients revealed a chicken-wing shaped LAA (67.6 %).
Procedural data
Procedural data related to the implantation of LAA oc-
clusion devices are summarized in Table 3. The primary
efficacy outcome measure in the Watchman™ group was
90.9 %, whereas it was 93.3 % in the ACP 2 group (p =
0.791). Only the Watchman™ device device could not be
implanted in two patients (9.1 %) either due to an ana-
tomical mismatch or due to an incomplete occlusion of
the LAA landing zone. In contrast, the ACP 2 device
was implanted in all patients with one patient with in-
complete ostial occlusion (6.7 %). More than one trans-
septal puncture was needed only in only one patient
(2.7 %) due to a transseptal retrieval of an intra-atrial
embolized Watchman™ occluder during the procedure.
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Table 1 Baseline characteristics of the study collective
Watchman ACP 2 All p Value
Patients, n (%) 22 (59.5) 15 (40.5) 37 (100) -
Male, n (%) 16 (72.7) 9 (60) 25 (67.6) 0.417
Age, y (IQR) 77 (70.75–81) 80 (76–83) 79 (71.5–81.5) 0.213
Height, cm (IQR) 170 (167.75–177) 170 (165–172) 170 (167–175) 0.090
Weight, kg (IQR) 80.5 (67.5–90) 83.5 (69.75–93.25) 81.5 (69.25–90) 0.531
Reason for not taking OAC, n (%)
- GI bleeding 8 (36.4) 8 (53.8) 16 (43.2) 0.306
- ICB 4 (18.2) 2 (13.3) 6 (16.2) 0.694
- Muscle bleeding 2 (9.1) 0 (0) 2 (5.4) 0.230
- Other bleeding localization 2 (9.1) 3 (20) 5 (13.5) 0.341
- Refusal 3 (13.6) 0 (0) 3 (8.1) 0.136
- Other causes 3 (13.6) 2 (13.3) 5 (13.5) 1.000
AF type, n (%)
- Paroxysmal 12 (54.5) 7 (46.7) 19 (51.4) 0.638
- Persistent 2 (9.1) 3 (20) 5 (13.5) 0.341
- Permanent 8 (36.4) 5 (33.3) 13 (35.1) 0.850
Heart rhythm at hospitalization, n (%)
- SR 6 (27.3) 6 (40) 12 (32.4) 0.225
- AF 12 (54.5) 9 (60) 21 (56.8) 0.742
- PM 2 (9.1) 0 (0) 2 (5.4) 0.230
- unsp. 2 (9.1) 0 (0) 2 (5.4) 0.230
Prior PVI, n (%) 2 (9.1) 1 (6.7) 3 (8.1) 0.791
Hypertension, n (%) 21 (95.5) 15 (100) 36 (97.3) 0.403
Diabetes mellitus, n (%) 6 (27.3) 6 (40) 12 (32.4) 0.417
TIA, n (%) 4 (18.2) 0 (0) 4 (10.8) 0.080
Stroke, n (%) 1 (4.5) 2 (13.3) 3 (8.11) 0.336
Coronary artery disease, n (%) 13 (59.1) 8 (53.3) 21 (56.8) 0.729
Peripheral vascular disease, n (%) 3 (13.6) 1 (6.7) 4 (10.8) 0.503
Renal failure, n (%) 8 (36.4) 5 (33.3) 13 (35.1) 0.850
- GFR (IQR) 70 (43.5–70) 70 (41–70) 70 (42–70) 0.636
Liver failure, n (%) 3 (13.6) 1 (6.7) 4 (10.8) 0.503
Prior bleeding, n (%) 16 (72.7) 13 (86.7) 29 (78.4) 0.312
Labile INR, n (%) 2 (9.1) 1 (6.7) 3 (8.1) 0.791
CHA2DS2-VASc score (IQR) 4 (3–5) 5 (3–5) 5 (3–5) 0.292
HAS-BLED score (IQR) 4 (3–5) 4 (3–4) 4 (3–5) 0.538
Baseline OAC, n (%)
- None 10 (45.5) 9 (60) 19 (51.4) 0.385
- Warfarin 3 (13.6) 3 (20) 6 (16.2) 0.606
- Rivaroxaban 6 (27.3) 2 (13.3) 8 (21.6) 0.312
- Dabigatran 1 (4.5) 1 (6.7) 2 (5.4) 0.779
- Apixaban 2 (9.1) 0 (0) 2 (5.4) 0.230
Cardiac device, n (%)
- PM 4 (18.2) 3 (20) 7 (18.9) 0.890
- ICD 1 (4.5) 2 (13.3) 3 (8.1) 0.336
Values are given as medians (25th and 75th percentiles) or total numbers (percentage). AF atrial fibrillation, GFR glomerular filtration rate, GI gastrointestinal, ICB
intracerebral bleeding, ICD implantable cardioverter defibrillator, INR international normalized ratio, OAC oral anticoagulation, PM pacemaker, PVI pulmonary vein
isolation, SR sinus rhythm, TIA transient ischemic attack, unsp. unspecified
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Pericardial effusion and subsequent intermittent circula-
tory failure with rapid hemodynamic stabilization with-
out the need for cardiopulmonary resuscitation occurred
in one patient of the Watchman™ group (2.7 %). All
these results showed no statistically significant difference
between the Watchman™ and the ACP 2 group.
In-hospital outcome and peri-procedural safety events
Table 4 shows all relevant data related to in-hospital out-
come and peri-procedural safety events. None of the pa-
tients died due to the implantation of LAA occlusion
devices. However, one patient with a preexisting highly
reduced left ventricular function (ejection fraction 28 %)
died from an acute heart failure linked to a severe
urosepis 20 days after the implantation (i.e., adverse
event). In another patient with non-ST elevation myo-
cardial infarction (NSTEMI) and percutaneous coronary
intervention (PCI) with stent implantation known clopi-
dogrel non-response, DAPT with ASA and ticagrelor
instead of clopidogrel was continued as an individual
treatment attempt.
Severe conduction blocks, such as BBB or AV blocks,
did not occur. Access site complications, such as groin
bruise and bleedings at the access sites represented
75.0 % of all complications. Most of them were mild,
corresponding to a BARC type 1 bleeding (76.5 % of all
bleeding complications) and only 1 case (2.7 % of all
patients) needed transfusion without the need for
Table 2 Baseline echocardiographic data
Watchman ACP 2 All p Value
LV function, n (%)
- Normal 14 (63.6)a 14 (93.3)a 28 (75.5) 0.039
- Mild impairment 6 (27.3)a 0 (0)a 6 (16.2) 0.027
- Moderate impairment 1 (4.5) 0 (0) 1 (2.7) 0.403
- Severe impairment 1 (4.5) 1 (6.7) 2 (5.4) 0.779
LVEDD, mm (IQR) 49 (44–54.25) 45.5 (40–49.5) 46.5 (42.25–53.75) 0.096
Aortic valve, n (%)
- Stenosis 2 (9.1) 2 (13.3) 4 (10.8) 0.638
- Regurgitation 10 (45.5) 3 (20) 13 (35.1) 0.111
Pulmonary valve, n (%)
- Stenosis 0 (0) 0 (0) 0 (0) -
- Regurgitation 0 (0) 1 (6.7) 1 (2.7) 0.220
Mitral valve, n (%)
- Stenosis 2 (9.1) 1 (6.7) 3 (8.1) 0.791
- Regurgitation 14 (63.6) 11 (73.3) 25 (67.6) 0.536
Tricuspid valve, n (%)
- Stenosis 0 (0) 0 (0) 0 (0) -
- Regurgitation 12 (54.5) 10 (66.7) 22 (59.5) 0.461
Aortic bulb diameter, mm (IQR) 31 (29–35.25) 31 (27.75–35.25) 31 (29–35) 0.737
LAA (IQR)
- Diameter, mm 48.5 (44.25–55) 40 (40–47.5) 46 (42.5–53) 0.193
- Plane, cm2 23 (18.5–28.25) 23 (14.5–28.75) 23 (17–28.5) 0.802
- Volume, ml 83.5 (66–101,75) 58.5 (46.75–99.5) 74.5 (57.5–101.75) 0.329
- Depth, mm 34 (27–38.75) 35 (27.5–40.75) 35 (28–40) 0.262
LAA ostial diameter, mm (IQR)
- 0° 18 (16–23) 20 (13.5–22) 18 (16–22) 0.797
- 45° 18 (16.25–21.75) 19 (14–21) 18 (16–21) 0.727
- 90° 18 (16.75–20.25) 20 (14.75–21) 18.5 (16–21) 0.754
- 135° 20 (16.5–22.5) 21 (17.25–22) 20 (17.25–22) 0.569
Landing zone, mm (IQR) 17 (13.5–21.5) 16 (13.5–19.5) 16 (13.75–20.5) 0.556
Values are given as medians (25th and 75th percentiles) or total numbers (percentage). LAA left atrial appendage, LV left ventricular, LVEDD left ventricular
end-diastolic dimension. aIndicating significant difference
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vascular surgery. The patient with a pericardial effusion
(3 mm) in the Watchman™ group could be treated conser-
vatively. Notably, neither peri-procedural nor in-hospital
transient ischemic attack, stroke or device thrombosis oc-
curred. Patients could have been discharged with a me-
dian of 4 days after the intervention. None of the
surviving patients developed persistent neurological or
heart-failure related disability.
Discussion
AF is one of the main causes leading to ischemic stroke
and persistent neurological disability. In almost 25 % of
patients developing an ischemic stroke AF can be docu-
mented by ECG recording [3]. Therefore effective pre-
vention of cerebral embolization represents the most
important aspect for an optimal treatment of patients
with AF. Besides the established vitamin K antagonists
such as warfarin, innovative DOACs emerged as reliable
treatment alternatives. In a current meta-analysis these
drugs were shown to reduce significantly the risk of
major cerebral bleedings and hemorrhagic stroke when
compared to warfarin [7, 24]. Specific subsets of pa-
tients of patients are prone to develop severe bleed-
ings as a consequence of OAC, for instance patients
with malignoma, major gastrointestinal bleedings and
geriatric patients with an increasing risk to fall in
everyday life. Accordingly, most of the patients within
the presented study revealed a history of severe bleed-
ings leading to the decision to implant an LAA occlu-
sion device. These patients revealed an increased
median HAS-BLED score of 4 points and still revealed
an increasing risk of developing stroke, as indicated by
an increased median CHA2DS2-VASc score of 5 points
corresponding to an estimated annual risk of
thromboembolic stroke of about 6.7 % [4].
Relative contraindications against the use of OAC
have been reported in about 20 % of patients with AF
[25, 26]. Even patients without any contraindication
against OAC are often not treated by the optimal anti-
thrombotic drug regimes [27, 28]. Within the present
study, half of the study patients were not anticoagulated
previously due to relevant contraindications. In these
patients exclusion of the LAA has become the therapy
of choice in order to prevent fatal thromboembolic events
apart from OAC [9, 29, 30]. Since we only enclosed pa-
tients with a high bleeding risk (a median HAS-BLED
score of 4 points indicates “high risk” [6]) or refusal for
OAC and, therefore, relative or absolute contraindication
for OAC, DAPT with ASA and clopidogrel following im-
plantation procedure was thought to be appropriate for
Table 3 Procedural data
Watchman ACP 2 All p Value
Success rate, n (%) 21 (95.5) 15 (100) 36 (97.3) 0.403
Complete ostial occlusion (i.e., gap < 5 mm), n (%) 20 (90.9) 14 (93.3) 34 (91.9) 0.791
Positioning attempts, n (IQR) 2.5 (1.75–3) 2 (1.5–5) 2 (2–3) 0.555
Changes of device size, n (IQR) 1 (1–1) 1 (1–2) 1 (1–1) 0.169
Final device size, mm (IQR) 24 (21–27) 25 (22–30) 24 (22–27) -
Duration, min. (IQR) 122.5 (75–136.25) 100 (80–110) 110 (76–135) 0.069
Fluoroscopy time, min. (IQR) 11.7 (7.4–16.8) 12.7 (9.5–17.7) 12.4 (8.5–16.9) 0.244
Reference dose, Gy*cm2 (IQR) 80.5 (45.75–103.25) 62 (52–89) 64 (49–96) 0.842
Amount of contrast agent, ml (IQR) 165 (130–202.25) 140 (110–180) 157 (110–195) 0.833
LAA configuration, n (%)
- Chicken-wing 14 (63.6) 11 (73.3) 25 (67.6) 0.536
- Windsock 3 (13.6) 1 (6.7) 4 (10.8) 0.503
- Broccoli 4 (18.2) 3 (20) 7 (18.9) 0.890
- Tub 1 (4.5) 0 (0) 1 (2.7) 0.403
Number of lobi, n (%)
- 1 4 (18.2) 3 (20) 7 (18.9) 0.890
- 2 13 (59.1) 10 (66.7) 23 (62.2) 0.641
- 3 1 (4.5) 0 (0) 1 (2.7) 0.403
- Multi 4 (18.2) 2 (13.3) 6 (16.2) 0.694
Days on ICU/IMC, n (IQR) 1 (1–1) 1 (1–1) 1 (1–1) 0.327
Post-procedural days in hospital, n (IQR) 3 (2.25–4) 4 (2.75–5.25) 4 (2.75–5) 0.341
Values are given as medians (25th and 75th percentiles) or total numbers (percentage). ICU intensive care unit, IMC intermediate care unit
Fastner et al. BMC Cardiovascular Disorders  (2016) 16:25 Page 6 of 9
these patients. The duration of DAPT lasted 6 months
as previously been shown to be an effective and safe an-
tithrombotic treatment [10].
Success rates of 95.5–100 %, respectively, were com-
parable to prior studies using the Watchman™ device
[9, 10] or were even higher for the ACP 2 [12, 14].
Since complete coverage of the LAA ostium is crucial
for preventing from embolization from the LAA, this
was defined as a primary efficacy outcome measure,
which was also beyond 90 % for both devices.
The documented high efficacy appears to be associated
with a careful and appropriate selection of device sizes
according to the pre- and peri-procedural measurements
of LAA dimensions being assessed by a multi-modal im-
aging approach with angiography and TEE imaging [14, 22]
allowed a safe and accurate peri-procedural guiding for an
optimal positioning and adaption. Diameters of the LAA
ostium, landing zone, angulation, deepness and volume ap-
peared most similar in recommended angulations (0, 45, 90
and 135°) with a tendency for larger orifice diameters being
measured at 135° of angulation [31]. The median size of the
devices was about 40 % larger than the median landing as
assessed by TEE, surpassing the 20 % range of recom-
mended oversizing [22].
One patient revealed a flat tub-shaped LAA morpho-
logy, which made implantation of both devices impos-
sible, whereas all other typical LAA morphologies were
able to be accessed by LAA occlusion devices. Even the
relatively frequent occurrence of the chicken-wing morph-
ology, described as often being a challenging morphology
for transcatheter occlusion device implantation [32], was
not seen to decrease the high success rates of both
devices. Time of fluoroscopy was comparable to prior
studies [18, 19] and did not differ significantly between
both groups despite the fact that decision making algo-
rithm in our study regarding accurate measurements of
the LAA and selection of the adequate device size was
based on peri-procedural 2D TEE in combination with
angiography. 3D TEE has been described as an additional
imaging technique for optimal visualization of cardiac
anatomy during percutaneous cardiac interventions
[22, 33]. However, efficacy data evaluating TEE (either
2D or 3D) versus sole or combined angiography during
implantation of LAA occlusion devices are not available
at present. Since the procedures were performed by ex-
perienced interventional cardiologists, well practiced in
LAA closure device implantation, we could not find a
certain learning curve neither concerning procedural
time nor related to peri-procedural complications [34].
Major peri-procedural complications were rare (8.1 %)
and did not reveal persistent disability. At 40.5 %, groin
hematomas and groin bleedings occurred more frequently
compared to recently published data [10, 18, 20]. How-
ever, the majority of access site bleedings were minor
hematomas (80.0 % of all access-site complications cor-
responded to a BARC type 1 bleeding). The majority of
patients suffering from access-site complications was
affected by combined arterial and venous access-site
bleedings (21.6 % of all patients). As must be expected,
the arterial access-site was the second most common
bleeding site (16.2 % of all patients). Since an arterial
access during LAA closure device implantation procedure
is not mandatory [35], a certain number of access-site
bleedings may be avoidable if this access way would be
abandoned. Notably, the arterial access allows a safer
performance [35] at the expense of some additional mild
hematomas. Only one patient was in need of blood trans-
fusion, whereas vascular surgery was never needed. With
respect to major complications, one case of circulatory
failure was linked to a post-procedural detected pericar-
dial effusion (3 mm), which could be treated conserva-
tively. Early device thrombosis followed by TIA or
stroke did not occur in our population suggesting that
DAPT initiated by a loading dose might be effective to
prevent thromboembolism at the intraluminal device
Table 4 Peri-procedural complications and safety events
Watchman ACP 2 All p Value
Overall complications, n (%) 11 (50) 9 (60.0) 20 (54.1) 0.549
Major complications, n (%) 3 (13.6) 0 (0) 3 (8.1) 0.136
Device embolization, n (%) 1 (4.5) 0 (0) 1 (2.7) 0.403
Circulatory failure, n (%) 2 (9.1) 0 (0) 2 (5.4) 0.230
- With CPR 1 (4.5) 0 (0) 1 (2.7) 0.403
- Without CPR 1 (4.5) 0 (0) 1 (2.7) 0.403
Bleeding complications, n (%) 8 (36.4) 9 (60.0) 17 (48.6) 0.157
- Groin bruise 4 (18.2) 5 (33.3) 9 (24.3) 0.292
- Groin bleeding 3 (13.6) 3 (20.0) 6 (16.2) 0.606
- Pericardial effusion 1 (4.5) 0 (0) 1 (2.7) 0.403
- Other (dental) 0 (0) 1 (6.7) 1 (2.7) 0.220
Access-site bleedings, n (%) 7 (31.9) 8 (53.3) 15 (40.5) 0.191
- Venous access 0 (0.0) 1 (6.7) 1 (2.7) 0.220
- Arterial access 4 (18.2) 2 (13.3) 6 (16.2) 0.694
- Both access-sites 3 (13.6) 5 (33.3) 8 (21.6) 0.153
BARC score, each n (%)
- Type 1 7 (31.8) 6 (40.0) 13 (35.1) 0.609
- Type 2 1 (4.5) 2 (13.3) 3 (8.1) 0.336
- Type 3a 0 (0.0) 1 (6.7) 1 (2.7) 0.220
- Type 3b 0 (0.0) 0 (0.0) 0 (0.0) -
- Type 3c 0 (0.0) 0 (0.0) 0 (0.0) -
- Type 4 - - - -
- Type 5a 0 (0.0) 0 (0.0) 0 (0.0) -
- Type 5b 0 (0.0) 0 (0.0) 0 (0.0) -
Values are given as total numbers (percentage). BARC score Bleeding Academic
Research Consortium score, CPR cardiopulmonary resuscitation
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site prior to neo-endothelialization. One patient with
intra-procedural device dislodgement in the left atrium
(Watchman™ group) which could be successfully re-
trieved by a veno-venous double lasso interventional
technique.
Limitations of the study
This study is based on observational registry data con-
cerning a relative small real-life patient population and
was not intended to reliable calculate significant differ-
ences between both device types. Comparison results of
both devices are for informative reasons only. The aim
was to demonstrate essential peri-interventional efficacy
and safety data concerning LAA occlusion device im-
plantation in general. A subsequent enlarged set of this
registry data might be able to evaluate further differences
between both devices.
As this observational study focused on the peri-
procedural time, the follow-up period was limited to the
discharge from hospital.
The application of any of the two devices was not ran-
domly assessed and was based on the operator’s discretion
being mainly based on LAA anatomic considerations. In
contrast, this more individualized and clinically driven de-
cision algorithm might have strongly influenced the high
achievement of primary efficacy outcome measure, which
realistically reflects clinical and interventional practice in
experienced centers.
Conclusions
Transcatheter implantation of LAA occlusion devices
appears to be a feasible and safe percutaneous cardiac
intervention with a rare occurrence of major complications
and a high success rate in a real-life patient population.
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